OncoViRx is a discovery-stage, pharmaceutical start-up within the University of Pennsylvania’s UPstart program. In collaboration with the Robertson and Winkler Laboratories at the University’s Perelman School of Medicine and School of Arts & Sciences, we are focused on discovering and developing novel small molecule therapies for the treatment of a range of hematologic malignancies (blood cancers). Specifically, we are working on compounds that inhibit the c-MYC, NF-ΚB, and Notch1 pathways, and anticipate initial clinical development will be in several sub-types of relapsed/refractory non-Hodgkin’s lymphoma and/or acute myeloid leukemia.
OncoViRx’s discovery and IP platform is based on more than 10 years of research developing preclinical datasets for therapeutic compounds. Based on the high-throughput screening of compounds from the U.S. Cancer Institute’s Developmental Therapeutics Program, 40 small molecule drug candidates have been identified, and several were advanced into a pilot animal study with promising results.
Two of these compounds, which are in the same class, have been selected for further development, and the Winkler Laboratory is now developing analogs of these compounds. Our goal is to develop novel treatments that are efficacious, have reduced short and long term side effect profiles, and are cost effective.